ALK-POSITIVE NSCLC

Clinical trials for ALK-POSITIVE NSCLC explained in plain language.

Never miss a new study

Get alerted when new ALK-POSITIVE NSCLC trials appear

Sign up with your email to follow new studies for ALK-POSITIVE NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug combo tested for Tough-to-Treat lung cancer

Disease control Ongoing

This study is testing the safety and initial effectiveness of combining two drugs, ceritinib and nivolumab, for adults with advanced ALK-positive non-small cell lung cancer. It aims to find the best dose and see if the combination helps shrink tumors. The trial involves 57 partic…

Matched conditions: ALK-POSITIVE NSCLC

Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 17, 2026 13:09 UTC

ALK-POSITIVE NSCLC

Get alerted when new ALK-POSITIVE NSCLC trials appear

New drug combo tested for Tough-to-Treat lung cancer